ABT-102 - CAS 808756-71-0
Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
CAS Number:
ABT 102 is a selective transient receptor potential vanilloid 1 (TRPV1) receptor antagonist with IC50 values to be 5-7 nM. No recent reports of development identified for phase-I development in Pain in USA.
Molecular Weight:
Molecular Formula:
Quality Standard:
In-house standard
Canonical SMILES:
TRP Channel
Current Developer:
Originator Abbott Laboratories
Chemical Structure
CAS 808756-71-0 ABT-102

Related TRP Channel Products

(CAS: 1254205-52-1)

RQ-00203078 is a potent, selective and orally active TRPM8 antagonist (IC50 values are 5.3 and 8.3 nM for rat and human channels respectively). RQ-00203078 bloc...

CAS 55224-94-7 AP18

(CAS: 55224-94-7)

AP18 is a selective Transient receptor potential A1(TRPA1) channel blocker which reversibly inhibits TRPA1 with IC50 values of 3.1 and 4.5 µM at human and mouse...

CAS 942206-85-1 GSK1016790A

(CAS: 942206-85-1)

GSK1016790A is a novel and potent transient receptor potential vanilloid 4 (TRPV4) agonist. It has been used to demonstrate a role for TRPV4 in regulating urina...

(CAS: 1332708-14-1)

PF-4840154 has been foundd to be superior than Mustard Oil as a TrpA1 agonists. IC50: 97 nM and 23 nM (EC50) for hTrpA1 and rTrpA1 respectively.

CAS 348575-88-2 Optovin

(CAS: 348575-88-2)

Optovin is a reversible photoactive TRPA1 activator; stimulates human TRPA1 channels in vitro and enables repeated photoactivation of motor behaviors in wild-ty...

CAS 808756-71-0 ABT-102

(CAS: 808756-71-0)

ABT 102 is a selective transient receptor potential vanilloid 1 (TRPV1) receptor antagonist with IC50 values to be 5-7 nM. No recent reports of development iden...

(CAS: 1333210-07-3)

SAR7334, a TRPC6 inhibitor, could be valuable in studying sorts of diseases related to TRPC.

SN 2
(CAS: 823218-99-1)

SN 2 is a novel and potent small molecule activator of TRPML3. Its EC50 value is 1.13 uM. It had a similar synergistic effect and reached up-to 10-fold enhancem...

SAR7334 hydrochloride
(CAS: 1333207-63-8)

The hydrochloride salt form of SAR7334, a TRPC6 inhibitor, could be valuable in studying sorts of diseases related to TRPC.

PF 05105679
(CAS: 1398583-31-7)

PF-05105679 is a selective TRPM8 Antagonist with clinical efficacy in cold-related pain. IC50 value is 103 nM. It shows >100-fold selectivity for TRPM8 over a p...

CAS 138977-28-3 Capsazepine

(CAS: 138977-28-3)

Capsazepine, a benzazepine derivative, has been found to be a sensory neurone excitotoxin that could be used against hyperalgesic responses. IC50: 562 nM (Rat T...

(CAS: 5465-86-1)

ML204 is a novel and potential TRPC4 Channel inhibitor. ML204 inhibited TRPC4β-mediated intracellular Ca(2+) rise with an IC(50) value of 0.96 μm and exhibited ...

CAS 472981-92-3 SB-366791

(CAS: 472981-92-3)

SB-366791 is a potent, and selective cinnamide TRPV1 antagonist (pA2 = 7.71 at hVR1) with IC50 of 5.7±1.2 nM.

(CAS: 245747-08-4)

Pyr6, a pyrazole derivative, is a selective inhibitor of ransient receptor potential cation 3 (TRPC3) channels that inhibited Orai1- and TRPC3-mediated Ca(2+) e...

CAS 404-86-4 (E)-Capsaicin

(CAS: 404-86-4)

Capsaicin, the major pungent ingredient found in hot red chili peppers of the genus Capsicum, suppresses the growth of several malignant cell lines.

CAS 393514-24-4 BCTC

(CAS: 393514-24-4)

BCTC is a TRPA1 and TRPV1 antagonist that inhibits capsaicin-induced and acid-induced activation of rat TRPV1 with IC50 values of 35 and 6 nM, respectively.

(CAS: 878811-00-8)

MK-2295 is a potent TRPV1 antagonist. TRPV1 antagonists has the potential as analgesic and anti-inflammatory agents.

CAS 68489-09-8 WS12

(CAS: 68489-09-8)

WS12 is a potent TRPM8 agonist. It acts as a cooling agent with EC50 value of 193 nM. It robustly activated TRPM8 in low micromolar concentrations, thus display...

(CAS: 1041478-78-7)

AMG8562 is a novel vanilloid receptor TRPV1 modulator.

CAS 501951-42-4 SB705498

(CAS: 501951-42-4)

SB705498 is a TRPV1 antagonist for hTRPV1, antagonizes capsaicin, acid, and heat activation of TRPV1 with IC50 of 3 nM, 0.1 nM and 6 nM, shows a degree of volta...

Reference Reading

1.Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials.
Othman AA1, Nothaft W, Awni WM, Dutta S. Br J Clin Pharmacol. 2013 Apr;75(4):1029-40. doi: 10.1111/j.1365-2125.2012.04405.x.
AIM: To characterize quantitatively the relationship between ABT-102, a potent and selective TRPV1 antagonist, exposure and its effects on body temperature in humans using a population pharmacokinetic/pharmacodynamic modelling approach.
2.Formulation design and evaluation of amorphous ABT-102 nanoparticles.
Jog R1, Kumar S1, Shen J1, Jugade N2, Tan DC2, Gokhale R2, Burgess DJ3. Int J Pharm. 2016 Feb 10;498(1-2):153-69. doi: 10.1016/j.ijpharm.2015.12.033. Epub 2015 Dec 15.
Amorphous nanoparticles are able to enhance the kinetic solubility and concomitant dissolution rates of BCS class II and BCS class II/IV molecules due to their characteristic increased supersaturation levels, smaller particle size and greater surface area. A DoE approach was applied to investigate formulation and spray drying process parameters for the preparation of spray dried amorphous ABT-102 nanoparticles. Stability studies were performed on the optimized formulations to monitor physical and chemical changes under different temperature and humidity conditions. SLS/soluplus(®) and SLS/PVP K25 were the best stabilizer combinations. Trehalose was used to prevent nanoparticle aggregation during spray drying. Particle size distribution, moisture content, PXRD, PLM, FTIR and in vitro dissolution were utilized to characterize the spray dried nanoparticle formulations. The formulations prepared using soluplus(®) showed enhanced dissolution rate compared to those prepared using PVP K25.
3.The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility.
Frank KJ1, Westedt U, Rosenblatt KM, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M. Int J Nanomedicine. 2012;7:5757-68. doi: 10.2147/IJN.S36571. Epub 2012 Nov 12.
Amorphous solid dispersions (ASDs) are a promising formulation approach for poorly soluble active pharmaceutical ingredients (APIs), because they ideally enhance both dissolution rate and solubility. However, the mechanism behind this is not understood in detail. In the present study, we investigated the supramolecular and the nano/microparticulate structures that emerge spontaneously upon dispersion of an ASD in aqueous medium and elucidated their influence on solubility. The ASD, prepared by hot melt extrusion, contained the poorly soluble ABT-102 (solubility in buffer, 0.05 μg/mL), a hydrophilic polymer, and three surfactants. The apparent solubility of ABT-102 from the ASD-formulation was enhanced up to 200 times in comparison to crystalline ABT-102. At the same time, the molecular solubility, as assessed by inverse equilibrium dialysis, was enhanced two times. Asymmetrical flow field-flow fractionation in combination with a multiangle light-scattering detector, an ultraviolet detector, and a refractometer enabled us to separate and identify the various supramolecular assemblies that were present in the aqueous dispersions of the API-free ASD (placebo) and of binary/ternary blends of the ingredients.
4.Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials.
Othman AA1, Nothaft W, Awni WM, Dutta S. J Clin Pharmacol. 2012 Jul;52(7):1028-41. doi: 10.1177/0091270011407497. Epub 2011 May 12.
ABT-102 is a selective TRPV1 antagonist with robust efficacy in several preclinical models of pain. Three phase 1 studies evaluated ABT-102 pharmacokinetics upon oral administration to healthy human volunteers: a single-dose study (2, 6, 18, 30, and 40 mg) and a multiple-dose study (2, 4, and 8 mg twice daily for 7 days) using a solution formulation and a multiple-dose study (1, 2, and 4 mg twice daily for 7 days) using a solid-dispersion formulation. These studies followed double-blind, randomized, placebo-controlled designs. ABT-102 exhibited dose- and time-linear pharmacokinetics. ABT-102 half-life ranged from 7 to 11 hours, and steady state was achieved by day 5 of dosing. Population analysis of the pharmacokinetic data from the 3 studies was conducted. A 1-compartment model with a transit compartment for absorption and first-order elimination provided best fit to the data. The model included formulation-dependent lag times and a bioavailability factor (F(rel)) for solution relative to solid dispersion.